News , Weight management ,

New human clinical study on InnoSlim® supports adiponectin and AMPK activation

Aug 8 , 2022 - Josh Beaty
New human clinical study on InnoSlim® supports adiponectin and AMPK activation

BREA, CA – NuLiv Science announced new research developments from a new human clinical study based on its IP ingredient, InnoSlim®. The fat oxidation ingredient is a plant-based compound that helps regulate glucose and lipid metabolism through the adiponectin and AMPK signaling pathway.

The newest human clinical study, published in the Journal of Biochemistry and Biotechnology, examined the effects of InnoSlim® on hyperglycemia and dyslipidemia regulation and its mechanism of action in pre-diabetic with hyperlipidemia human participants. The randomized, double-blind, crossover clinical trial measured fasting blood glucose and lipids, oral glucose-tolerance-test, small dense low-desnsity lipoprotein-cholesterol (sdLDL-C), high-density lipoprotein-cholesterol (HDL-C), adiponectin, HbA1C, and adenosine monophosphate-activated protease kinase (AMPK).

After 6 weeks of InnoSlim® supplementation, fasting blood glucose and area under the curve (AUC) were significantly decreased by 10.1% and 12.69% (p<0.05), respectively. Triglycerides and sdLDL-C were significantly decreased by 31.06% and 19.96% (p<0.05), respectively, in the InnoSlim® group than in the placebo group. HDL-C, adiponectin, and AMPK were significantly increased by 11.78%, 22.07%, and 12.72% (p<0.05), respectively in the InnoSlim® group than in the placebo group. The results demonstrate that oral supplementation with InnoSlim® reduces hyperglycemia and dyslipidemia without adverse events.

Richard Wang, president at Nuliv Science, noted: “Outcomes of our two trials to date suggest InnoSlim® may support glucose and cholesterol health as well as weight management. Insulin resistance increases hunger and leads to more food intake. We’ve seen that InnoSlim® reduced insulin resistance and increased fatty acid breakdown and can be part of an effective weight management program when accompanied by lower caloric intake, increased physical activities, quality sleep, and absence of underlying hormonal imbalance, and chronic inflammation. We’re excited to see how this ingredient helps consumers with their metabolic health journey.”

With these new insights, the future is bright for health and wellness brands.

“For more than 10 years we have been speaking to clients about incorporating InnoSlim® into their weight management products. A few clients jumped on the innovation of InnoSlim® and saw their repeat shoppers come back and order more units as they saw their hard work at the gym get that boost from InnoSlim®. With the encouragement of the early adopters, we dove deeper into the mechanism of getting stubborn fat off of the body. Two human clinical trials, with multiple in-vitro and in-vivo studies later, we have demonstrated from the petri dish on a cellular level to direct human benefit.”, shared Ken Montes, vice president of business development.

NuLiv Science specializes in the research and development of proprietary and clinically proven nutraceutical ingredients via traditional and western scientific processes. Since 1997, the company has served its customers’ sourcing and research needs with an emphasis on quality and efficacy.

* * *

InnoSlim® human study – Journal of Biochemistry & Biotechnology